Background: Allergic asthma is a heterogeneous chronic inflammatory disease of the airways with a massive infiltration of eosinophils or neutrophils mediated by allergen-specific T H 2 and T H 17 cells, respectively. Therefore successful treatment of allergic asthma will require suppression of both T H 2 and T H 17 cells. Objective: We sought to investigate the role of the T H 17 cell pathway in regulating T H 2 cell responses in allergic asthma. Methods: Allergic asthma was induced by intranasal challenge with proteinase allergens in C57BL/6, Il17a 2/2 Il17f 2/2 , and retinoic acid receptor-related orphan receptor gt (RORgt) Asthma is a heterogeneous disease of the lung and airway characterized by distinct symptoms, such as airway hyperresponsiveness, mucus production, infiltration of inflammatory granulocytes, and shortness of breath, which could be lifethreatening. 1, 2 The prevalence of this disease has markedly increased over the past several decades, and it has become one of the major global health problems, affecting approximately 300 million persons worldwide. 1 Asthma can be categorized into allergic and nonallergic asthma based on the types of triggering stimuli. 3 Allergic asthma is a common form of asthma caused by sensitization against allergens, such as pollen, house dust mites, fur dander from pets, or fungi, whereas nonallergic asthma is caused by irritants, such as tobacco smoke, ozone, diesel exhaust particles, or airborne virus. 1, 4 Allergic asthma has been considered to be mediated by T H 2 cells; however, recent studies uncovered the involvement of T H 17 cells as an additional critical contributor in the pathogenesis of allergic asthma in animal models and human subjects. 5 T H 2 cells mediate eosinophilic asthma by secreting type 2 cytokines, such as IL-4, IL-5, IL-9, and IL-13. These cytokines induce B-cell isotype switching to IgE (IL-4), recruit eosinophils (IL-5) and mast cells (IL-9 and IL-13) into the lung and airway, and induce goblet cell hyperplasia and tissue remodeling (IL-13), leading to airway hyperresponsiveness. 2, 6 On the other hand, T H 17 cells have been regarded as a critical mediator of steroid-resistant neutrophilic asthma. [7] [8] [9] Increased IL-17A levels were observed in the lungs of patients with asthma, and these were positively correlated with neutrophilic inflammation, increased airway hyperresponsiveness, and a steroid-resistant type of severe asthma. 10 A mixed T H 2 and T H 17 cell response in the airways has been associated with the severity of allergic asthma. 9, 11 IL-17A stimulates airway epithelial cells to secrete the chemokines CXCL1 and CXCL8, which in turn recruit neutrophils. 12 In addition, IL-17A causes airway remodeling through upregulation of a-smooth muscle actin in fibroblasts. 13 Hence T H 2 and T H 17 cells exert nonredundant pathogenic roles during the development of allergic asthma by inducing eosinophilic and neutrophilic inflammation, respectively.
Because of their critical contributions to the development of allergic asthma, a number of experimental and clinical studies have addressed whether blockade of either the T H 2 or T H 17 cell pathway ameliorates clinical symptoms of the disease. In particular, multiple clinical trials have demonstrated that antibodies against T H 2 cell cytokines (IL-4, IL-5, and IL-13) and their receptors in patients with moderate-to-severe asthma had limited clinical benefits. For instance, antibodies to IL-5 or its receptor are generally effective in reducing eosinophilia, whereas they have little to no effect on airway hyperresponsiveness.
14 Antibodies to IL-13 or its receptor lead to reduced airway hyperresponsiveness, with little effect in eosinophilia. 15, 16 More recently, a human mAb to IL-17RA did not improve asthmatic symptoms in patients with moderate-to-severe asthma. 17 In this regard Choy et al 18 recently reported that antibodies to T H 2 cell cytokines enhance T H 17 cell responses and neutrophilia, whereas anti-IL-17A enhances T H 2 cell responses and eosinophilia in animal models of allergic asthma. This study indicates that pulmonary T H 2 and T H 17 cell responses are mutually regulated and suggests that blockade of the T H cell pathway alone leads to exaggeration of the other pathway. Supporting this notion, GATA-3 and IL-13 are shown to inhibit T H 17 cell differentiation. 19, 20 Hence combined blockade of both T H 2 and T H 17 cell pathways might be considered to achieve therapeutic benefits in controlling asthma without adverse effects.
In the present study we aimed to investigate the role of the T H 17 pathway in regulating T H 2 cell responses in allergic airway inflammation by using an animal model of proteinase-induced allergic asthma. We also aimed to investigate the clinical relevance of blocking the T H 17 pathway by analyzing T cells from patients with allergic asthma.
METHODS

Ethics statements
Animal experiments, including induction of allergic lung inflammation in Il17a Cre R26R eYFP mice, and IL-17F reporter mice (Il17f rfp ) were described previously. [21] [22] [23] All mice were maintained in a specific pathogen-free facility at Seoul National University or MD Anderson Cancer Center. Mice aged 6 to 12 weeks were used.
Reagents
Ursolic acid (UA), busulfan (Sigma-Aldrich, St Louis, Mo) and SR2211 (Calbiochem, Nottingham, United Kingdom) were dissolved in dimethyl sulfoxide (DMSO). For in vitro use, UA and SR2211 were further diluted with PBS (GenDEPOT, Barker, Tex). In vitro cell cultures of lymphoid cells were performed in RPMI 1640 supplemented with 10% FBS (Gen-DEPOT), 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, 55 mmol/L 2-mercaptoethanol, and 10 mg/mL gentamicin. For PLAT-E cell cultures, Dulbecco modified Eagle medium supplemented with 10% FBS, 1 mg/mL puromycin, and 10 mg/mL blasticidin was used. All cell-culture reagents, except FBS, were the products of Gibco (Carlsbad, Calif).
Animal models of allergic asthma
To induce allergic lung inflammation, we adopted an animal model of proteinase-induced allergic asthma induced by repeated intranasal challenge with fungal proteinase allergens. 24 In brief, mice were anesthetized with isoflurane (Terrell; Piramal, Bethlehem, Pa) and challenged intranasally with 7 mg of proteinase from Aspergillus oryzae (PAO; Sigma-Aldrich) plus 20 mg of ovalbumin (OVA; Grade V from Sigma-Aldrich) in 50 mL of PBS every other day for 4 times (days 0, 2, 4, and 6). For the therapeutic model, mice were challenged on days 0, 2, 4, 6, and 12. In experiments with UA, mice were injected intraperitoneally with 150 mg/kg UA dissolved in DMSO or DMSO alone as a vehicle control. In some experiments UA was injected on days 0, 2, 4, and 6 in preventive format and days 6, 8, 10, and 12 in therapeutic format as described in Fig E1, A and C, in this article's Online Repository at www.jacionline.org. For IFN-g neutralization, anti-mouse IFN-g (XMG1.2; Bio X Cell, West Lebanon, NH) or rat IgG 1 (HRPN; Bio X Cell) as an isotype control were injected intraperitoneally (200 mg per mouse per injection) on days 0, 2, 4, and 6. Twenty-four hours after the last challenge, mice were killed with CO 2 for further analysis.
For chronic asthma models, we injected mice with intranasal PAO/OVA and intraperitoneal UA on days 0, 2, 4, 11, and 13 (see Fig E2, A, in this article's Online Repository at www.jacionline.org). Alternatively, we intraperitoneally immunized mice with an OVA-alum mixture (100 mg of OVA, Imject Alum; Thermo Scientific, Waltham, Mass) on days 0 and 14 and injected them with intranasal OVA (50 mg) and intraperitoneal UA on days 25, 26, and 27 (see Fig E2, E) . Twenty-four hours after the last challenge, mice were killed with CO 2 for further analysis.
Analysis of bronchoalveolar lavage fluid
A 20-gauge IV catheter (BD Biosciences, San Jose, Calif) was inserted into the trachea and flushed twice with 500 and 800 mL of cold PBS to collect bronchoalveolar lavage (BAL) fluid. Cytokine levels were determined by means of ELISA with first-flushed 500 mL of BAL fluid. Ten thousand cells in BAL fluid were attached on the slide by Cytopro Centrifuge (Wescor; Logan, Utah) and stained with Diff-Quik staining kits (Sysmex, Kobe, Japan), according to the manufacturer's protocol. Absolute numbers of macrophages, eosinophils, neutrophils, and lymphocyte in BAL fluid were calculated based on total cell counts.
Analysis of lymphoid cells in the lung
The left lobe of the lung was used for histologic analysis. The rest of the lobes were placed in 3 mL of RPMI 1640 containing 0.5 mg/mL collagenase (Type IV; Gibco), 2 mg/mL Dispase (Gibco), and 25 U/ml DNase I (Bio Basic, Markham, Ontario, Canada). Lungs were first dissociated with the gentle-MACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) and then digested for 30 minutes at 378C with continuous agitation, followed by a second dissociation with the gentleMACS Dissociator. Cells were filtered through 100-mm nylon mesh and washed with cold PBS containing 1.5% FBS. Lymphoid cells were further isolated by using lymphocyte separation medium (MP Biomedicals, Santa Ana, Calif), according to the manufacturer's instructions.
Histology
The left lobe of the lung was fixed in neutral buffered 10% formalin solution (Sigma) for at least 24 hours. Formalin-fixed samples were sent to the Pathology Center at Seoul National University College of Medicine for hematoxylin and eosin and periodic acid-Schiff staining.
Lymph node restimulation
The mediastinal lymph nodes were minced physically in cold PBS containing 1.5% FBS and filtered through a 100-mm nylon mesh. Lymphoid cells (1 3 10 6 /mL) were cultured in the presence of 0, 10, and 50 mg/mL OVA for 3 days. Culture supernatants were used for cytokine ELISA.
In vitro murine T H cell differentiation 
CD62L
high CD44 low cells with the FACSAria III cell sorter (BD Biosciences) and stimulated with plate-coated anti-CD3 (1 mg/mL, 145-2C11: Bio X Cell) and soluble anti-CD28 (2 mg/ mL, 37.51; Bio X Cell) for 4 days. For T H 2 differentiation, IL-2 (10 ng/mL; eBioscience, San Diego, Calif) and IL-4 (10 ng/mL; PeproTech, Rocky Hills, NJ) were added. For IFN-g neutralization experiment, anti-IFN-g (5 mg/mL, XMG1.2; Bio X Cell) was added also. 
Quantitative real-time PCR
BCL6 knockdown in naive T cells by means of retroviral infection
Retroviral supernatants were made by transfecting PLAT-E cell lines with either negative control LMP vector or 2 kinds of LMP-shBcl6. Transfection was performed with FuGene HD transfection reagent (Promega, Madison, Wis), according to the manufacturer's protocol. Naive T cells were sorted from splenocytes and stimulated with plate-bound aCD3 and soluble aCD28. For T H 2 differentiation, IL-2, IL-4, and aIFN-g were added. After 24 hours, cells were infected with retroviral supernatants containing 8 mg/mL Polybrene by means of spin infection (1000g for 60 minutes at 308C). After spin infection, cells were washed with PBS and again placed on the aCD3-coated plate with the same initial T H 2 differentiating condition. After another 72 hours, cells were analyzed for cytokine production by using flow cytometry.
Flow cytometry and antibodies
For intracellular cytokine analysis, cells were stimulated with phorbol 12-myristate 13-acetate (100 ng/mL; Sigma-Aldrich) and ionomycin (1 mmol/L; Sigma-Aldrich) plus Brefeldin A and monensin (both from eBioscience) before staining. IC fixation buffer and permeabilization buffer from eBioscience were used for intracellular cytokine staining, and the Foxp3 staining kit (eBioscience) was used for BCL6 staining, according to the manufacturer's instructions. Samples were analyzed with the FACSVerse flow cytometer (BD Biosciences), and acquired data were analyzed with FlowJo software (TreeStar, Ashland, Ore). The following antibodies were used for flow cytometric analysis or cell sorting: Alexa Fluor 488-conjugated antibodies to mouse CD62L (MEL-14) and IFN-g (XMG1.2); fluorescein isothiocyanate-conjugated antibody to human CD45RA (HI100); phycoerythrinconjugated rat IgG 1 (eBRG1; eBioscience); antibodies to mouse CD25 (PC61), IL-17A (TC11-18H10.1), and mouse/human BCL6 (IG191E/A8); peridinin-chlorophyll-protein complex/Cy5.5-conjugated antibodies to mouse CD4 (GK1.5), CD45.1 (A20), and IFN-g; phycoerythrin/Cy7-conjugated antibodies to mouse IL-13 (eBio13A; eBioscience), mouse/human CD44 (IM7), human CD4 (OKT4), and CD45RO (UCHL1); allophycocyanin (APC)-conjugated antibodies to mouse/human IL-5 (TRFK5), human CD25 (BC96), and IL-4 (8D4-8; eBioscience); Alexa Fluor 647-conjugated antibody to mouse IL-4 (11B11); APC/Cy7-conjugated antibodies to mouse CD4 (GK1.5) and human CD3ε (OKT3); and Pacific blue-conjugated antibodies to mouse CD45.2 (104) and human CD4 (RPA-T4). In some experiments the frequency of IL-4-and/or IL-5-producing T H 2 cells was determined by staining cells with Alexa Fluor 647-and APC-conjugated antibodies before analyzing them with a same channel in the flow cytometer. IL-4-and/or IL-5-positive cells were designated as IL-4/5 1 cells.
ELISA
Cytokine levels in cultured supernatants or BAL fluid were measured by using ELISA kits, according to the manufacturer's protocol. For mouse IFN-g, IL-4, and IL-5, ELISA kits were from R&D Systems (Minneapolis, Minn) or BioLegend (San Diego, Calif). For mouse IL-17A, ELISA kits were from BioLegend. For mouse IL-13 and human IL-13 and IL-17A, ELISA kits were from eBioscience.
In vitro human naive CD4
1 T-cell differentiation and effector memory CD4
1 T-cell restimulation
Human peripheral blood was obtained from healthy volunteers who are not taking any medications. PBMCs were prepared by using lymphocyte separation medium (MP Biomedicals), according to the manufacturer's instructions. Subsequently, total CD4
1 T cells were isolated by means of negative selection with CD14 microbeads (Miltenyi Biotec), followed by positive selection with CD4 microbeads (Miltenyi Biotec). Naive and effector memory CD4
1
T cells were further sorted as
respectively, by using the FACSAria III cell sorter (BD Biosciences). For naive T-cell differentiation, naive T cells undergoing fluorescence-activated cell sorting (FACS) were stimulated with plate-coated anti-CD3 (10 mg/mL, OKT3; BioLegend) and soluble anti-CD28 (2 mg/mL, CD28.2; BioLegend) for 4 or 7 days. For T H 2 polarization, IL-2 (10 ng/mL), IL-4 (10 ng/mL), and anti-IFN-g (5 mg/mL, B27; BioLegend) were added. For T H 17 polarization, IL-2 (10 ng/mL), IL-6 (20 ng/mL), TGF-b (10 ng/mL), IL-23 (20 ng/ mL), IL-21 (20 ng/mL), IL-1b (20 ng/mL), anti-IFN-g (5 mg/mL), and anti-IL-4 (5 mg/mL, MP4-25D2; BioLegend) were added. TGF-b was from PeproTech, and the rest of the cytokines were from eBioscience. Effector memory CD4 1 T cells were stimulated with plate-coated anti-CD3 (10 mg/ mL) for 48 hours in the presence of UA or DMSO.
Human PBMC isolation and in vitro stimulation
Human peripheral blood was obtained from allergic asthmatic patients who meet the following criteria. First, asthma was diagnosed based on a positive bronchodilator response or methacholine provocation test result. Second, positivity of the Dermatophagoides farinae skin response was determined with skin prick tests by using the cutoff level of both a wheal size greater than 4 mm and an allergen/histamine wheal size ratio of 1 or greater. Third, systemic corticosteroids were not administrated in the most recent month. PBMCs were prepared by using Lymphocyte Separation Medium (MP Biomedicals), according to the manufacturer's instruction. Cells (2 3 10 5 ) were stimulated with 50 mg/mL HDM extract (D farinae; Greer Laboratories, Lenoir, NC) in the presence of 2 mmol/L UA or DMSO as a vehicle control for 7 days.
Fate mapping study ) were transferred to recipient mice on day 16. Asthma-induced B6.SJL congenic mice were assessed for IL-17A, IL-13, IL-4, and IFN-g expression by using intracellular staining.
Statistics
Data were graphed and analyzed with Prism 6 software (GraphPad Software, La Jolla, Calif). Statistical significance between 2 groups was determined by using the 2-tailed Student t test. For comparison of more than 3 groups, 1-way ANOVA and Tukey tests were used. P values of less than .05 were considered statistically significant. Wild-type and dKO mice were intranasally injected with mixtures of fungal PAO/OVA as a model allergen. Intranasal PAO/OVA is known to induce allergen-specific T H 2 cells, as well as T H 17 cells, in the airway, offering an ideal model to study the potential mutual regulation between the 2 T H cell subsets. [24] [25] [26] As expected, wild-type mice expressed increased levels of IL-17A and IL-17F producers among CD4
RESULTS
Il17a
1 T cells in the lungs, which were absent in dKO mice (Fig 1, A-C) . Of note, frequencies and numbers of T H 2 cells were also significantly diminished in the lungs of dKO mice, and frequencies and numbers of T H 1 cells were increased compared with those in wild-type mice (Fig 1, A-C) . IL-4 and IL-5 levels in BAL fluid from dKO mice were also significantly lower than those in wild-type mice (Fig 1, D) . A similar decrease in the frequency of T H 2 cells was also observed in A distinct T H 2-T H 17 cell population expressing both IL-17A and IL-4/IL-5 was observed in wild-type mice but not dKO mice (Fig 1, A) . This observation raised the hypothesis that the reduced T H 2 cell responses in dKO mice might be due to the lack of these T H 2-T H 17 cells originating from T H (Fig 1, B) and absolute numbers (Fig 1, C) of CD4 1 T-cell subsets. D, Levels of IFN-g, IL-4, and IL-5 in BAL fluid. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001. WT, Wild-type.
T H 17 cells did not become T H 2 cytokine-producing cells in the airway (see Fig E4, A, in this article's Online Repository at www.jacionline.org). Next, we adoptively transferred in vitrogenerated OVA-specific T H 17 cells purified from Il17f rfp 3OT-II mice 22 into congenic mice before challenging the recipient with intranasal OVA. Donor T H 17 cells appeared to be stable and did not produce T H 2 cytokines (see Fig E4, B and C) . These results together indicate that T H 2-T H 17 cells found in the airways of asthmatic mice are not derived from T H 17 cells and suggest that the reduced T H 2 cell responses in dKO mice are not due to the lack of T H 17 cells.
Retinoic acid receptor-related orphan receptor gtdeficient mice exhibit reduced T H 2 cell responses to allergens in the airway Because the lack of IL-17A and IL-17F showed reduced T H 2 cell responses in an animal model of allergic asthma, we hypothesized that T H 17 cell responses play a crucial role in generation of T H 2 cell responses. To further explore the role of T H 17 cell responses on T H 2 cells in allergic asthma, we sought to determine the role of retinoic acid receptor-related orphan receptor gt (RORgt), a signature transcriptional factor responsible for the T H 17 cell program, on T H 2 cell responses during the development of allergic asthma. We administered PAO/OVA intranasally in wild-type and Rorgt gfp/gfp (RORgt-deficient) mice. As expected, 27 RORgt-deficient mice showed a profound reduction in the frequency and number of T H 17 cells in the lung compared with wild-type mice (Fig 2, A-C) . Interestingly, RORgt-deficient mice also exhibited significantly diminished T H 2 cell populations, both in frequency and number, whereas those of T H 1 cells were increased compared with values in wild-type mice (Fig 2, A-C) . Consistently, amounts of IL-4, IL-5, and IL-17A were all significantly lower in BAL fluid of RORgt-deficient mice compared with that of wild-type mice (Fig 2, D) . Both eosinophil and neutrophil numbers in BAL fluid were also significantly reduced in the former group (Fig 2, E) . These results demonstrate that, in addition to diminished T H 17 cell responses and neutrophilia, RORgt-deficient mice did not mount optimal T H 2 cell responses and eosinophilia in this animal model of allergic asthma.
An RORgt inhibitor suppresses both T H 2 and T H 17 cell responses in allergic asthma
Diminished pulmonary T H 2 cell responses in RORgt-deficient mice prompted us to hypothesize that targeting RORgt might be effective in suppressing both T H 2 cell-and T H 17 cell-mediated inflammation in the airway. To test this possibility, we used the RORgt inhibitor UA, which has been shown to selectively inhibit RORgt in vitro and in vivo during T H 17 cell differentiation. 28 Groups of C57BL/6 mice were intranasally administered PAO/ OVA and additionally given UA or DMSO as a vehicle (see Fig  E1, A) . Consistent with the results observed in RORgt-deficient mice (Fig 2) , mice treated with UA had significantly reduced frequencies and numbers of T H 2 and T H 17 cells while having increased T H 1 cell frequencies and numbers in BAL fluid (Fig  3, A and B) . A similar tendency was also observed in CD4
1 T cells in the lung (data not shown). When lymphoid cells from the mediastinal lymph nodes were restimulated with OVA, CD4
1 T cells (Fig 2, B) and absolute numbers (Fig 2, C) of lung CD4 1 T-cell subsets. D, Levels of IFN-g, IL-4, IL-5, and IL-17A in BAL fluid. E, Absolute numbers of total cells, eosinophils (eo), macrophages (mac), lymphocytes (lym), and neutrophils (neu) in BAL fluid. Data are representative of 3 independent experiments. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001. ns, Not significant.
from UA-treated mice produced significantly lower levels of IL-4, IL-5, and IL-17 while producing significantly higher levels of IFN-g compared with those from vehicle-treated mice (see Fig  E1, B) . In addition, mice treated with UA exhibited significantly reduced eosinophil and neutrophil numbers in BAL fluid compared with those in vehicle-treated mice (Fig 3, C) . Moreover, the former group had significantly reduced infiltration of inflammatory cells around the airways with reduced mucus production than seen in the latter group (Fig 3, D) . Hence treatment with UA prevented development of T H 17 and T H 2 cell responses and blocked allergic inflammation in an animal model of allergic asthma. We next investigated whether the RORgt inhibitor can ameliorate allergic T-cell responses in asthmatic mice. Mice were intranasally administered PAO/OVA to establish allergic airway inflammation before being injected with UA or vehicle (see Fig E1, C) . Compared with mice treated with vehicle, mice treated with UA had a moderate but significant reduction in the frequencies and numbers of T H 17 and T H 2 cells in BAL fluid, whereas those of T H 1 cells were increased (Fig 3, E and F) . A similar tendency was also observed in OVA-restimulated lymphoid cells of the mediastinal lymph nodes (see Fig E1, D) . Consistent with reduced T H 2 and T H 17 responses in UA-treated mice, eosinophil and neutrophil numbers in BAL fluid were all remarkably lower (Fig 3, G) . Reduction of infiltrated inflammatory cell numbers and mucus production in the UA-treated mice were also observed (Fig 3, H) .
To further determine whether RORgt blockade ameliorates allergic T H 2 and T H 17 cell responses in more chronic settings, we used 2 additional allergic asthma models induced by repeated intranasal PAO/OVA challenges or by systemic sensitization with OVA and alum before subsequent challenges with intranasal (Fig 3, A and E) and absolute numbers (Fig 3, B and F) of BAL fluid CD4 1 T-cell subsets . Fig 3, C and G, Absolute numbers of total cells, macrophages (mac), eosinophils (eo), neutrophils (neu), and lymphocytes (lym) in BAL fluid. Fig 3, D and H, Histologic analysis of the lung. Data are representative of 3 independent experiments. H&E, Hematoxylin and eosin; PAS, periodic acid-Schiff. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001. ns, Not significant.
OVA (see Fig E2, A and E). In both models we observed a significant reduction in the numbers of both T H 17 and T H 2 cells in the BAL fluid of UA-treated mice compared with those in vehicletreated mice (see Fig E2, B and C, and E2, F and G, respectively). Consistently, eosinophil and neutrophil numbers in BAL fluid were profoundly lower in the former than in the latter (see Fig  E2, D and H) . Collectively, these results demonstrate that treatment with the RORgt inhibitor UA significantly ameliorated both eosinophilic and neutrophilic inflammation in the airways in animal models of allergic asthma associated with reduced T H 2 and T H 17 cell numbers.
Diminished T H 2 cell responses by RORgt blockade are not due to increased IFN-g levels
RORgt-deficient T cells and T cells from UA-treated mice produced higher levels of IFN-g compared with their respective control T cells. Because IFN-g is a strong inhibitor of T H 2 cell differentiation, 29 it is possible to surmise that the increased IFN-g levels led to diminished T H 2 cell responses in UA-treated mice. To address this possibility, we examined whether neutralizing IFN-g restores T H 2 cell responses in the UA-treated mice. Compared with control IgG treatment, we observed that anti-IFN-g treatment significantly decreased the frequency of IFN-g producers among CD4
1 T cells in the UA-treated mice, indicating the IFN-g-neutralizing effect of the antibody (Fig 4, A) . By contrast, we observed comparable frequencies and numbers of T H 2 and T H 17 cells between the control IgG-and anti-IFNg-treated groups in the UA-treated mice (Fig 4, A and B) . Consistently, differential cell counts in BAL fluid also showed that mice treated with UA exhibited reduced eosinophilia and neutrophilia regardless of anti-IFN-g treatment (Fig 4, C) . Thus the reduction of T H 2 cell responses by the RORgt inhibitor is independent of IFN-g.
T cell-intrinsic function of RORgt in T H 2 cell differentiation
The observed diminished pulmonary T H 2 cell responses in RORgt-deficient mice and UA and aIFN-g-treated mice led us to hypothesize that RORgt regulates T H 2 cell differentiation in a T cell-intrinsic manner. To determine whether RORgt plays any role in pulmonary T H 2 cell responses in a T cell-intrinsic manner in vivo, we generated mixed bone marrow chimeric mice by transferring a 1:1 mixture of wild-type (CD45.1 1 ) and RORgt-deficient (CD45. 2 1 ) bone marrow cells into bone marrow-ablated Tcrb 2/2 mice (Fig 5, A) . After reconstitution, the chimeric mice were intranasally challenged with PAO/OVA. Compared with wild-type CD4
1 T cells, RORgt-deficient CD4 1 T cells exhibited significantly reduced T H 2 and T H 17 cell responses in the lung and BAL fluid while exhibiting increased T H 1 cell responses (Fig 5, B and C) . Hence RORgt in T cells is required for optimal differentiation of T H 2 cells in the airway in vivo.
To further investigate the T cell-intrinsic role of RORgt in differentiation of T H 2 cells, we used an in vitro T H 2 cell differentiation system in which naive CD4 1 T cells from Rorgt gfp/gfp mice were stimulated with plate-coated aCD3 in the presence of soluble aCD28, IL-2, and IL-4. Of note, RORgt-deficient T cells showed a significantly lower frequency of IL-4/IL-5-producing T H 2 cells than wild-type T cells (Fig 5, D) . The production of IL-13 and IL-5 in the cultured supernatants was also significantly decreased in RORgt-deficient T cells (Fig 5, E) . In addition, this inefficient differentiation of RORgt-deficient T cells into T H 2 cells was independent of IFN-g because anti-IFN-g treatment had little effect on the production of IL-13 and IL-5 (data not shown).
To further examine the role of RORgt in the T H 2 cell program, we analyzed mRNA transcript levels known to be associated with T H cell differentiation. Consistent with the protein data, we observed a significant reduction in levels of Il4, Il5, and Il13 transcripts in RORgt-deficient T cells compared with those of wildtype T cells (Fig 5, F) . Levels of Gata3 and Irf4 were also slightly reduced in RORgt-deficient T cells. Interestingly, we observed that Bcl6 expression was significantly higher in RORgt-deficient T cells than wild-type T cells. These data demonstrate that RORgt-deficient T cells express lower levels of T H 2 cell signature genes but express a higher level of Bcl6 than wild-type T cells under T H 2 cell differentiation conditions.
Because we observed an increased expression of Bcl6 transcript in the RORgt-deficient T cells under T H 2-skewing conditions in vitro, we investigated whether RORgt-deficient T cells expressed increased BCL6 in vivo. To this end, we compared BCL6 expression in CD44 hi CD62L
2
CD4
1 T cells between Rorgt 1/gfp and Rorgt gfp/gfp mice. Compared with heterozygotes, RORgt-deficient mice had an increased frequency of BCL6-expressing cells among effector/memory CD4 1 T cell population (Fig 5, G) . When the CD44 hi CD62L
2
CD4
1 T cells were subjected to plate-coated anti-CD3 stimulation, RORgt-deficient T cells produced significantly less IL-4, IL-13, and IL-17A than wild-type T cells, whereas IFN-g levels were comparable (Fig  5, H) . Collectively, RORgt deficiency resulted in increased (Fig 4, A) and absolute number (Fig 4, B) of BAL fluid CD4
1 T-cell subsets. C, Absolute numbers of total cells, macrophages (mac), eosinophils (eo), neutrophils (neu), and lymphocytes (lym) in BAL fluid. Data are representative of 3 independent experiments. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001. ns, Not significant.
expression of BCL6 in effector memory T cells associated with diminished T H 2 and T H 17 cytokine production at steady state in vivo.
Downregulation of Bcl6 restores T H 2 cell differentiation in RORgt-deficient T cells
Because BCL6 is known to suppress the differentiation of naive T cells into T H 2 cells, 30 we hypothesized that the increased Bcl6 expression accounts for the decreased T H 2 cell differentiation in RORgt-deficient T cells. To test this hypothesis, we used 2 retroviral short hairpin RNA constructs targeting Bcl6 and found that they significantly diminished the expression of BCL6 (Fig 6, A) . As depicted in Fig 6, B , knockdown of BCL6 in RORgt-deficient T cells resulted in a remarkable increase in the frequency of IL-13-producing T H 2 cells during T H 2 cell differentiation in vitro. Wild-type or BCL6-deficient naive CD4
1 T cells were subjected to T H 2 cell-skewing conditions to directly investigate the role of BCL6 in T H 2 cell differentiation. BCL6-deficient naive CD4
1 T cells exhibited an increase in the frequency of IL-4/IL-5-and IL-13-producing cells compared with that of wild-type CD4 1 T cells (Fig 6, C) . Consistently, amounts of IL-5 and IL-13 in supernatants were significantly greater in the BCL6-deficient than wildtype T cells, whereas IL-4 production was comparable (Fig 6,  D) . Thus downregulation of BCL6 restores the decreased T H 2 differentiation in RORgt-deficient T cells. These results strongly support the notion that RORgt facilitates T H 2 cell differentiation by inhibiting BCL6 expression. 
CD4
1 T cells were stimulated with plate-coated aCD3, and levels of the indicated cytokines were measured. Data are representative of at least 2 independent experiments. The graph shows means 6 SEMs. WT, Wild-type. *P < .05, **P < .01, and ***P < .001. nd, Not detected.
Effects of RORgt inhibition in human T H 2 cell differentiation
Finally, we sought to determine the effects of RORgt inhibition on the differentiation of human T H 2 cells from naive CD4 1 T cells. Naive CD4 1 T cells from healthy donors were stimulated under T H 17 or T H 2 cell differentiation conditions in the presence or absence of UA. As expected, 28 RORgt inhibition by UA almost completely suppressed IL-17A production under T H 17-skewing conditions (Fig 7, A) . To check the effects of RORgt inhibition on restimulation of effector/memory T H 17 cells, CD3
CD45RO
1 T cells from the same healthy volunteers were stimulated with plate-bound CD3 antibody. IL-17A production was significantly suppressed by the addition of UA in culture (Fig 7, A) . In addition, we also observed that addition of UA into the T H 2-skewing culture significantly inhibited the production of IL-13 compared with vehicle control (Fig 7,  B) . Consistently, the frequency of IL-4 1 cells was significantly reduced in UA-treated T cells compared with that in vehicletreated T cells (Fig 7, C) . However, we observed no detectable levels of IL-13 from the supernatants of anti-CD3-stimulated effector/memory CD4 1 T cells (Fig 7, B) . Similarly, another RORgt inhibitor, SR2211, was found to inhibit the differentiation of human T H 2 and T H 17 cells in vitro (see Fig E5 in this article' s Online Repository at www.jacionline.org). 31 We next sought to explore whether inhibition of RORgt suppresses allergen-specific effector memory T H 2 and T H 17 cells in asthmatic patients. Allergic asthmatic patients were selected based on their response against the house dust mite allergen D farinae in skin prick tests. PBMCs from the patients were simulated with 50 mg/mL D farinae extract in the presence of DMSO or UA before IL-17A and IL-13 levels were measured. As shown in Fig 7, D , addition of UA significantly reduced production of IL-17A from D farinae-specific CD4 1 T cells. By contrast, no evident difference was observed in IL-13 levels between the DMSO-and UA-treated cells, indicating that RORgt inhibition has little role in suppressing allergen-specific effector/memory T H 2 cells. Together, these results demonstrate that RORgt inhibition resulted in suppression of both T H 2 and T H 17 cell differentiation from naive T cells while exerting little to no suppressing effector/memory T H 2 cell responses in human subjects.
DISCUSSION
Despite the nonredundant pathogenic roles of T H 2 and T H 17 cells in allergic airway inflammation, it has been unclear how the simultaneous inhibition of these 2 T H cell subsets can be achieved. Our findings in the present study are that (1) Il17a 2/2 Il17f 2/2 dKO mice showed reduction of T H 17 and T H 2 cell responses on proteinase allergen challenge, (2) RORgt-deficient mice exhibited significantly diminished T H 2 and T H 17 cells in the airway in response to proteinase allergen, (3) pharmacologic inhibition of RORgt also inhibited T H 2 and T H 17 cell responses in the airway in wild-type mice in an IFNg-independent and T cell-intrinsic manner, (4) inhibition of T H 2 cell responses in RORgt-deficient T cells was restored by knockdown of BCL6, and (5) pharmacologic inhibition of RORgt also inhibited human T H 2 and T H 17 cell differentiation. Overall, our findings indicate that RORgt blockade can simultaneously suppress T H 2 and T H 17 cell responses during allergic asthma. independent experiments. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001.
Among diverse animal models of allergic asthma, we used a PAO/OVA-induced asthma model because this model exhibits both T H 2 and T H 17 cell-mediated allergic airway inflammation, offering an ideal model to study any mutual regulation between T H 2 and T H 17 cell responses. 25 In addition, proteinase allergens used in this model contains very low amounts of endotoxin, minimizing allergen-independent inflammation, which likely interferes with interpretation of T H 2 and T H 17 cell-mediated responses. 32 RORgt-deficient mice lack lymph nodes 33 ; therefore the reduced induction of T H 2 cell responses in RORgt-deficient mice could be due to the lack of airway-draining lymph nodes where antigen-induced T-cell differentiation occurs rather than a role of RORgt in T H 2 cell differentiation. To address this issue, we examined T H 2 cell responses in RORgt-deficient T cells in the mixed chimeric Tcrb 2/2 mice given a 1:1 mixture of bone marrow cells from wild-type and RORgt-deficient mice, which have normal secondary lymphoid organs, including airway draining lymph nodes, and found that RORgt-deficient T cells still exhibited a profound reduction in T H 2 cell responses on intranasal allergen challenges. Therefore we concluded that RORgt in T cells is required for optimal T H 2 cell responses in vivo.
Because T H 2 and T H 17 cell responses play critical and nonredundant roles in the pathogenesis of allergic asthma, there have been a number of attempts to block either pathway in animal models, as well as in human subjects. 15 However, blocking either the T H 2 or T H 17 pathway with anti-IL-13 or anti-IL-17 alone has been shown not to be sufficient for the treatment of allergic asthma because such treatment resulted in upregulation of the other pathway. 18 Similarly, a recent study by Park et al 34 demonstrated that coadministration of anti-IL-17 and anti-IL-13 reduced both T H 2 and T H 17 cell responses in the lung in an animal model of antigen-induced pulmonary arterial remodeling, whereas anti-IL-17 or anti-IL-13 alone resulted in upregulation of T H 2 or T H 17 downstream effector genes, respectively. Collectively, these reports imply that simultaneous targeting of both T H 2 and T H 17 cell responses would be a promising strategy for the treatment of allergic asthma, whereas targeting either pathway alone might be ineffective because of activation of the other pathway.
In this regard our previous study examined whether blockade of signal transducer and activator of transcription 3 (STAT3) inhibits both T H 2 and T H 17 cell responses in the airway because the activation of STAT3 is indispensable for T H 17 cell differentiation 35, 36 and STAT3 has been shown recently to be required for optimal T H 2 cell differentiation. 37 Although STAT3-deficient T cells exhibited reduced T H 2 and T H 17 cell differentiation in the bronchial 1 T cells was increased in RORgt-deficient mice at steady state. The antagonism between BCL6 and RORgt or GATA-3 is well documented. BCL6 functions as a transcriptional repressor antagonizing the function of RORgt, as well as the expression of Gata3, leading to inhibition of T H 17 and T H 2 cell differentiation, respectively. 40, 41 In addition, BCL6-deficient mice have more robust T H 2 cell-mediated inflammatory responses than wild-type mice, 42 and IL-13 is the most downregulated molecule by BCL6. 43 Importantly, we found that knockdown of BCL6 significantly restored the frequency of IL-13 producers in RORgt-deficient T cells under T H 2-skewing conditions, indicating that the increased BCL6 expression in the absence of RORgt played a critical role in the observed diminished T H 2 cell responses.
Thus we propose that RORgt blockade inhibits T H 2 cell responses, at least in part by inducing the expression of BCL6 in T cells. At this moment, it is not clear how RORgt regulates BCL6, and further studies are needed to identify the underlying molecular mechanisms. To rule out any possible nonredundant and compensatory functions between IL-17A and IL-17F, [44] [45] [46] [47] we used Il17a 2/2 Il17f 2/2 dKO mice in our allergic asthma model and found a significantly reduced T H 2 cell response in the airways of dKO mice in vivo. Il17a 2/2 Il17f 2/2 dKO mice still have intact RORgt, suggesting that the observed diminished T H 2 cell responses in dKO mice are not likely associated with reduced RORgt expression. Thus we speculate that the mechanism governing the reduced T H 2 cell responses in dKO mice differs from that induced by RORgt deficiency. It is possible that IL-17A and IL-17F stimulate the production of soluble factors, such as complement, 48 that could facilitate T H 2 cell responses from nonimmune cells in the lung. Hence we propose that both RORgt and T H 17 cytokines contribute to the generation of T H 2 cell responses in the airway, presumably through distinct mechanisms. BCL6 is essential for the generation of follicular helper T cells, 49 as well as follicular regulatory T cells. 50, 51 Hence one can speculate that RORgt can also play an important role in controlling germinal center reactions by modulating the expression of BCL6 in follicular helper T cells, follicular regulatory T cells, or both. Further studies will be needed to dissect the role of RORgt in germinal center reactions.
Importantly, we observed that pharmacologic inhibition of RORgt by UA also decreased significantly the differentiation of human T H 2 and T H 17 cells. UA is known to inhibit activation of STAT3 and nuclear factor kB in addition to RORgt; however, it specifically inhibits RORgt but not STAT3 or nuclear factor kB concentrations of less than 2 mmol/L, the concentration we used in the present study. 28 We also observed that another RORgt inhibitor, SR2211, also inhibited human T H 2 cell differentiation. Together with the results obtained with RORgt-deficient T cells, these findings strongly support the notion that RORgt blockade suppresses the T H 2 cell differentiation program in mice and human subjects. In addition, the same treatment also suppressed production of allergen-induced IL-17A from the PBMCs of patients with allergic asthma. Production of T H 2 cell cytokines from the PBMCs of patients with allergic asthma was not affected by treatment with the RORgt inhibitor. Clinical longitudinal studies reported that monosensitized children with atopic asthma become polysensitized over time, indicating that new allergen-specific T H 2 or T H 17 cells continuously develops over the course of time. 52, 53 Hence, although inhibition of RORgt is less efficient in controlling established memory T H 2 responses, it could eventually be beneficial for treatment of established allergic asthma by suppressing newly developing T H 2 and T H 17 cells. Supporting this notion, we observed that treatment with the RORgt inhibitor reduced all aspects of allergic asthma in our therapeutic model.
In summary, our study has unveiled a crucial role of RORgt in differentiation of T H 2 cells in allergic asthma. Based on our findings, we propose that targeting RORgt would be beneficial for the treatment of T H 2 cell-mediated eosinophilic asthma, as well as T H 17 cell-mediated neutrophilic asthma. Further immunologic and pharmacologic studies will be needed to identify effective RORgt inhibitors with few side effects before considering therapeutic use for allergic asthma in human subjects.
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Key messages
d RORgt in T cells is necessary for optimal T H 2 cell responses during allergic asthma.
d Inhibition of T H 2 cell responses in RORgt-deficient T cells depends on BCL6.
d Targeting RORgt might be a promising strategy for the treatment of allergic asthma through concomitant suppression of T H 2 and T H 17 cells in the airway.
FIG E2.
Effects of UA on a chronic asthma model. A and E, Schematic diagrams of experimental protocol for the chronic model using PAO/OVA (Fig E2, B-D) and OVA-alum (Fig E2, F-H) , respectively. B, C, F, and G, Frequencies (Fig E2, B and F) and absolute numbers (Fig E2, C and G) of BAL fluid CD4 1 T-cell subsets. D and H, Absolute numbers of total cells, macrophages (mac), eosinophils (eo), neutrophils (neu), and lymphocytes (lym) in BAL fluid. The graph shows means 6 SEMs. *P < .05, **P < .01, and ***P < .001. (Fig E4, B) and transferred into B6.SJL congenic mice (CD45.1 1 ) before challenging the recipients with allergens. Frequencies of BAL fluid CD4 1 T-cell subsets were analyzed by using flow cytometry (Fig E4, C) . Data are representative of 2 independent experiments (n 5 3-4 per experiment). 
